Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Economic information and modeling report

Modeling overview

24 evidence topics · 17 sources

Summary: published economic evaluations

No cost-effectiveness analysis, budget impact model, or health technology assessment of obefazimod was identified as of November 2026, and no obefazimod price has been announced. Published U.S. evaluations address the advanced therapies obefazimod would join. The Institute for Clinical and Economic Review (ICER) 2020 review modeled six targeted immune modulators and two biosimilars in moderate-to-severe ulcerative colitis with a Markov model of eight-week cycles, a health care sector perspective, a lifetime horizon, and 3% annual discounting. Cost per QALY ranged from $186,000 (infliximab-dyyb) to $1,870,000 (adalimumab); in the biologic-experienced population, the incremental cost-effectiveness ratio against conventional treatment ranged from $495,000 (tofacitinib) to $1,885,000 (adalimumab). ICER's five-year potential budget impact analysis of ustekinumab estimated that about 21% of eligible patients could be treated at wholesale acquisition cost, and about 51% at estimated net price, without crossing its threshold of approximately $819 million per year.

Bloudek et al. evaluated 21 treatment sequences in the base case and found infliximab or a biosimilar first line optimal by net health benefit and cost minimization. ICER's 2026 special assessment of Entyvio for the Centers for Medicare & Medicaid Services (CMS) used a lifetime Medicare model and found 30-day price premiums for Entyvio over infliximab in ulcerative colitis of $420 to $550 across thresholds of $50,000 to $200,000 per evLY, and no price premium supported over ustekinumab. Gulati et al. estimated cost per remission for mirikizumab and ustekinumab as second-line therapy from a U.S. commercial payer perspective. Shaffer et al. found that continuing 5-aminosalicylate with a biologic or tofacitinib was dominated by monotherapy. A review of 40 cost and health care resource use studies by Cichewicz et al. reported that biologic costs were not always offset by lower disease management costs and that switching and dose escalation increased drug costs. Each of these models is a candidate structure for a plan's obefazimod evaluation, and each would need an obefazimod price, which does not yet exist, and comparative efficacy inputs.

Summary: inputs available and absence of an obefazimod price or model

No budget impact model of obefazimod was identified, and Abivax has published no price. A plan building its own model can draw the eligible population from the U.S. prevalence of ulcerative colitis, 378 per 100,000, or 0.64% of Medicare fee-for-service beneficiaries. No recent peer-reviewed estimate of the moderately to severely active share exists; ICER's 2020 model used 22%, from the Crohn's and Colitis Foundation. Advanced-therapy uptake among patients newly diagnosed with ulcerative colitis in 2019 to 2023 was 27% at 1 year and 38% at 5 years. Abivax estimates about 271,000 U.S. advanced-therapy patients in 2025 and about 300,000 moderate-to-severe patients on conventional therapy or steroids only, and its research names that conventional-therapy group as the population in which physicians would likely start obefazimod.

The obefazimod price figures available are analyst assumptions: LifeSci Capital assumed a U.S. net annual price at launch of US$78,000, increased from US$66,000. Comparator costs available from public sources include ICER's January 2026 Medicare inputs (annual maintenance net cost $39,423 for intravenous vedolizumab, $27,221 for subcutaneous ustekinumab biosimilar, and $5,430 for an intravenous infliximab biosimilar in ulcerative colitis), the Medicare negotiated price for Stelara of $4,695.00 per 30-day supply, and wholesale acquisition costs reported to California for tofacitinib, upadacitinib, ozanimod, etrasimod, risankizumab, mirikizumab, and vedolizumab. Medicare negotiated prices for Entyvio and Xeljanz, selected for negotiation, take effect beginning in 2028. Non-drug inputs (colectomy $33,871 per admission; health-state costs) come from ICER's 2020 model. These inputs differ in date, price basis (list, net, or negotiated), and payer, so a plan would need to align them before use.

Targeted immune modulators versus conventional treatment: peer-reviewed summary of the ICER 2020 model

“We evaluated the cost-effectiveness from the U.S. health care sector perspective of the 6 TIMs and 2 biosimilars over a lifetime time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average net pricing estimates for TIMs with oral and subcutaneous modes of administration were obtained from SSR Health. For IV-administered TIMs, we used Centers for Medicare & Medicaid Services average sales prices (ASP) plus 9.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“cost-effectiveness was closest to $150,000 per quality-adjusted life-year (QALY) for infliximab and its biosimilars: infliximab-dyyb and infliximab-adba ($212,000, $186,000 and $195,000 per QALY, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the biologic-experienced population (Table 2), the incremental cost-effectiveness ratio compared with conventional treatment was highest for adalimumab ($1,885,000) and lowest for tofacitinib ($495,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The primary limitations of our cost-effectiveness analysis included restricted data availability, a paucity of information on treatment sequencing or switching, and our need to base outcomes for conventional treatment solely on the results from the placebo arms of the trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Ustekinumab: ICER U.S. potential budget impact analysis, 2020

“We used the cost-effectiveness model to estimate the potential total budgetary impact of the recently expanded indication of ustekinumab for prevalent individuals in the US” (opens the source at this quote in a new tab)

“Potential budget impact was defined as the total differential cost of using this new therapy rather than relevant existing therapies for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events.” (opens the source at this quote in a new tab)

“All costs were undiscounted and estimated over a five-year time horizon, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.” (opens the source at this quote in a new tab)

“the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately $819 million per year for new drugs.” (opens the source at this quote in a new tab)

“approximately 21% of eligible patients could be treated in a given year without crossing the ICER budget impact threshold of $819 million at the WAC of ustekinumab. Approximately 51% of eligible patients could be treated without crossing the budget impact threshold at its estimated net price.” (opens the source at this quote in a new tab)

Annualized per-patient budget impact over five yearsAt list priceAt net priceAt $150,000/QALY priceAt $100,000/QALY priceAt $50,000/QALY price
Ustekinumab“$73,600”“$53,100”“$28,800”“$27,600”“$26,400”
Market basket (55% biologic-naive, 45% biologic-experienced)“$37,500”“$37,500”“$37,500”“$37,500”“$37,500”
Net impact“$36,100”“$15,600”“-$8,700”“-$9,900”“-$11,100”

Wholesale acquisition costs of risankizumab, tofacitinib, and vedolizumab reported to California, 2026

Wholesale acquisition costs of upadacitinib and ozanimod reported to California, January 2025

Wholesale acquisition costs of etrasimod and mirikizumab at introduction, October 2023